Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MIL93 injection in locally advanced or metastatic solid tumors
CTR20202436Phase 2Active
- Sponsor
- Mabworks Biotech
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of MIL93 in Nonhematologic neoplasms, sponsored by Mabworks Biotech. Started Apr 2021; status: active.
02
Drugs
MIL93
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20202436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202436.